Clinical Trials Logo

Filter by:
NCT ID: NCT02049073 Withdrawn - Clinical trials for Noise-induced Hearing Loss

Prevention of Noise-induced Hearing Loss

Start date: October 31, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

Noise-induced hearing loss affects an estimated 5% of the worldwide population, with 30-40 million Americans exposed to hazardous sound or noise levels regularly. Sources of noise may be occupational, blast noise, or recreational. Trauma to the inner ear can occur through transient hearing loss or permanent hearing loss. Although hearing recovers after temporary transient hearing loss, growing evidence suggests that repeated temporary transient hearing loss may lead to a permanent hearing loss. Currently, there are no treatments and there are no known medications that can be used clinically to prevent noise-induced hearing loss in humans. The long-term goal of this research is to find medications that can prevent noise-induced hearing loss. The purpose of the present pilot study is to evaluate zonisamide and methylprednisolone as medications to prevent temporary transient hearing loss in humans.

NCT ID: NCT02048982 Withdrawn - Clinical trials for Prescribing Tendencies

What Influences Physicians' Decisions - Statistics or Stories?

Start date: February 2014
Phase: N/A
Study type: Interventional

The purpose of this study is to test whether physicians change their use of non-recommended tests, procedures, or medications more in response to evidence based-guidelines, price information, or an individual patient's story.

NCT ID: NCT02048969 Withdrawn - Liver Cirrhosis Clinical Trials

Treatment of Hepatic Encephalopathy With Flumazenil and Change in Cortical GABA Levels in MRS

Start date: June 2014
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to test feasibility of measuring flumazenil-induced changes in cortical GABA levels observed with localized 1H-MRS in relation to changes in severity of hepatic encephalopathy (HE) in subjects with non-alcoholic liver cirrhosis. This study is a double-blind, placebo-controlled, randomized, cross-over design.

NCT ID: NCT02048943 Withdrawn - Clinical trials for Unspecified Adult Solid Tumor, Protocol Specific

Dovitinib Lactate, Gemcitabine Hydrochloride, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Solid Tumors or Pancreatic Cancer

Start date: March 2015
Phase: Phase 1
Study type: Interventional

This phase I trial studies the highest and safest doses of dovitinib lactate, paclitaxel albumin-stabilized nanoparticle formulation, and gemcitabine hydrochloride when given together. Dovitinib lactate disrupts the activity of fibroblast growth factor receptors and reduces cancer growth and spread. Gemcitabine hydrochloride and paclitaxel albumin-stabilized nanoparticle formulation are anti-cancer drugs for treating many cancer types.

NCT ID: NCT02048163 Withdrawn - Cystic Fibrosis Clinical Trials

Intermittent Versus Continuous Infusion Meropenem in Cystic Fibrosis

Start date: December 2013
Phase: Phase 4
Study type: Observational

The purpose of this study is to compare the incidence of nausea and vomiting following short intermittent versus prolonged intermittent infusion of meropenem.

NCT ID: NCT02048111 Withdrawn - Hemophilia B Clinical Trials

Study of Recombinant Factor IX Product, IB1001, in Previously Treated Subjects With Hemophilia B

Start date: March 2014
Phase: Phase 3
Study type: Interventional

To evaluate the safety (acute adverse effects associated with infusions, and inhibitor development), pharmacokinetics (PK), and efficacy with respect to breakthrough bleeding and control of hemorrhaging during prophylaxis of IB1001 in subjects with hemophilia B.

NCT ID: NCT02048085 Withdrawn - Clinical trials for Acute Coronary Syndrome

Comparing Ticagrelor and Clopidogrel Pharmacodynamics After Thrombolysis

TACAT
Start date: January 2, 2014
Phase: Phase 4
Study type: Interventional

This study involves doing platelet function testing in patients who have undergone fibrinolysis. Fibrinolysis (Use of clot busting medicine in heart attack) is the standard of care to restore blood flow in blocked arteries as soon as possible after the "Heart attack" in rural health center where access to cardiac catheterization is one hour away. Fibrinolysis is done by the emergency room physician in a timely fashion to minimize the damage of the myocardium. Additionally anti-platelet regimen as adjuvant for patient undergoing fibrinolysis has been well studied in many trials. In this study investigators will use clopidogrel or ticagrelor in randomized fashion to evaluate anti- platelet effect by measuring efficacy in vivo (pharmacodynamics) and blood levels of both drugs (Pharmacokinetics).

NCT ID: NCT02047877 Withdrawn - Clinical trials for Acute Respiratory Distress Syndrome

Airway Inflammatory Response During Illness in Children With Respiratory Failure

Start date: July 2017
Phase: N/A
Study type: Observational

The purpose of this study has two major goals: 1) to measure the amount of two specific hormones interleukin (IL)-10 and interleukin (IL)-12p70 in mucous and blood; and 2) compare the hormone levels in two specific areas of the lung called the trachea (upper airway) and the bronchioles (lower airway). The hormones IL-10 and IL-12p70 are cytokines, special hormones cells use to communicate with each other during inflammation or infection. Cytokines can be measured in mucous and blood. The balance of one cytokine compared to another help doctors to understand how people respond differently to infection. Unfortunately, the amount of IL-10 and IL-12p70 is not known in children, especially children with a lung infection. In addition, we do not know if the balance of these cytokines differ in various regions of the lung. We believe the balance of IL-10 and IL-12p70 is similar whether measured in the upper or lower airways.

NCT ID: NCT02047552 Withdrawn - Anemia Clinical Trials

RCT of Goal-directed Iron Supplementation of Anemic, Critically Ill Trauma Patients, With and Without Oxandrolone

Start date: January 2015
Phase: Phase 2
Study type: Interventional

The purpose of this trial is to determine if the combination of goal directed iron supplementation and hepcidin mitigation can safely eliminate both the serum and bone marrow iron debt of anemic, critically ill trauma patients with functional iron deficiency.

NCT ID: NCT02046551 Withdrawn - Nicotine Dependence Clinical Trials

Atomoxetine's Effects On Nicotine Response And Stress Response In Smokers

Start date: April 2014
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate atomoxetine's effects on the rewarding and reinforcing effects of nicotine in a controlled human laboratory study with 24 otherwise healthy nicotine dependent subjects. It is hypothesized that atomoxetine will attenuate the negative effects of nicotine.